PT  - JOURNAL ARTICLE
AU  - Hangping Yao
AU  - Xiangyun Lu
AU  - Qiong Chen
AU  - Kaijin Xu
AU  - Yu Chen
AU  - Linfang Cheng
AU  - Fumin Liu
AU  - Zhigang Wu
AU  - Haibo Wu
AU  - Changzhong Jin
AU  - Min Zheng
AU  - Nanping Wu
AU  - Chao Jiang
AU  - Lanjuan Li
TI  - Patient-derived mutations impact pathogenicity of SARS-CoV-2
AID  - 10.1101/2020.04.14.20060160
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.14.20060160
4099  - http://medrxiv.org/content/early/2020/04/19/2020.04.14.20060160.short
4100  - http://medrxiv.org/content/early/2020/04/19/2020.04.14.20060160.full
AB  - The sudden outbreak of the severe acute respiratory syndrome–coronavirus (SARS-CoV-2) has spread globally with more than 1,300,000 patients diagnosed and a death toll of 70,000. Current genomic survey data suggest that single nucleotide variants (SNVs) are abundant. However, no mutation has been directly linked with functional changes in viral pathogenicity. We report functional characterizations of 11 patient-derived viral isolates. We observed diverse mutations in these viral isolates, including 6 different mutations in the spike glycoprotein (S protein), and 2 of which are different SNVs that led to the same missense mutation. Importantly, these viral isolates show significant variation in cytopathic effects and viral load, up to 270-fold differences, when infecting Vero-E6 cells. Therefore, we provide direct evidence that the SARS-CoV-2 has acquired mutations capable of substantially changing its pathogenicity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funds from Major Project of Zhejiang Provincial Science and Technology Department #2020C03123, National Science and Technology Major Project for the Control and Prevention of Major Infectious Diseases in China (2018ZX10711001, 2018ZX10102001, 2018ZX10302206), and start-up funds from Life Sciences Institute at Zhejiang University;Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full-genome sequences of the 11 viral isolates have been deposited to the GISAID collection with the following IDs: EPI_ISL_415709, EPI_ISL_416042, EPI_ISL_416044, EPI_ISL_416046, EPI_ISL_415711, EPI_ISL_416047, EPI_ISL_416425, EPI_ISL_416473, EPI_ISL_416474, EPI_ISL_418990, and EPI_ISL_418991.